FRTX
Price:
$0.74
Market Cap:
$4.42M
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements...[Read more]
Industry
Biotechnology
IPO Date
1993-03-10
Stock Exchange
NASDAQ
Ticker
FRTX
According to Fresh Tracks Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -14.73%. This represents a change of -8.68% compared to the average of -16.14% of the last 4 quarters.
The mean historical ROE of Fresh Tracks Therapeutics, Inc. over the last ten years is -104.85%. The current -14.73% ROE has changed -85.95% with respect to the historical average. Over the past ten years (40 quarters), FRTX's ROE was at its highest in in the September 2023 quarter at 19.22%. The ROE was at its lowest in in the December 2019 quarter at -143.41%.
Average
-104.85%
Median
-45.34%
Minimum
-342.55%
Maximum
-19.88%
Discovering the peaks and valleys of Fresh Tracks Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 927.68%
Maximum Annual ROE = -19.88%
Minimum Annual Increase = -80.03%
Minimum Annual ROE = -342.55%
Year | ROE | Change |
---|---|---|
2023 | -57.34% | -80.03% |
2022 | -287.20% | 81.00% |
2021 | -158.67% | 105.98% |
2020 | -77.03% | -77.51% |
2019 | -342.55% | 927.68% |
2018 | -33.33% | 63.52% |
2017 | -20.38% | 2.55% |
2016 | -19.88% | -2.32% |
2015 | -20.35% | -35.93% |
2014 | -31.76% | -37.56% |
The current ROE of Fresh Tracks Therapeutics, Inc. (FRTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-167.74%
5-year avg
-184.56%
10-year avg
-104.85%
Fresh Tracks Therapeutics, Inc.’s ROE is greater than Assembly Biosciences, Inc. (-121.46%), greater than Instil Bio, Inc. (-37.44%), greater than Nuvation Bio Inc. (-108.68%), greater than Achilles Therapeutics plc (-54.57%), greater than NextCure, Inc. (-62.50%), less than Comera Life Sciences Holdings, Inc. (67.46%), greater than SAB Biotherapeutics, Inc. (-94.37%), greater than Processa Pharmaceuticals, Inc. (-195.22%), greater than Third Harmonic Bio, Inc. (-14.46%), greater than Unicycive Therapeutics, Inc. (-374.14%), greater than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Cardio Diagnostics Holdings, Inc. (-258.81%), greater than Virax Biolabs Group Limited (-115.10%), greater than PaxMedica, Inc. Common Stock (-3167.06%), greater than SAB Biotherapeutics, Inc. (-94.37%), greater than Senti Biosciences, Inc. (-154.84%), greater than Cingulate Inc. (-113174.53%), less than Bellicum Pharmaceuticals, Inc. (33.22%), greater than Hillstream BioPharma, Inc. (-172.28%), greater than Blue Water Vaccines, Inc. (-126.11%), greater than Revelation Biosciences, Inc. (-311.33%), less than Kiora Pharmaceuticals, Inc. (21.31%),
Company | ROE | Market cap |
---|---|---|
-121.46% | $93.56M | |
-37.44% | $142.85M | |
-108.68% | $949.12M | |
-54.57% | $46.85M | |
-62.50% | $24.31M | |
67.46% | $6.15K | |
-94.37% | $37.84M | |
-195.22% | $2.85M | |
-14.46% | $465.00M | |
-374.14% | $69.56M | |
-126.19% | $2.45M | |
-258.81% | $40.84M | |
-115.10% | $7.47M | |
-3167.06% | $696.27K | |
-94.37% | $461.46K | |
-154.84% | $19.13M | |
-113174.53% | $15.61M | |
33.22% | $778.33K | |
-172.28% | $4.17M | |
-126.11% | $3.41M | |
-311.33% | $2.51M | |
21.31% | $9.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fresh Tracks Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Fresh Tracks Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Fresh Tracks Therapeutics, Inc.'s ROE?
How is the ROE calculated for Fresh Tracks Therapeutics, Inc. (FRTX)?
What is the highest ROE for Fresh Tracks Therapeutics, Inc. (FRTX)?
What is the 3-year average ROE for Fresh Tracks Therapeutics, Inc. (FRTX)?
What is the 5-year average ROE for Fresh Tracks Therapeutics, Inc. (FRTX)?
How does the current ROE for Fresh Tracks Therapeutics, Inc. (FRTX) compare to its historical average?